• Primidone (Mysoline): Advanced Neuroinhibition and ALS Bioma

  2026-05-23

  Explore the cutting-edge mechanisms and translational potential of Primidone (Mysoline) in neurodegenerative research. This article offers a deep dive into its unique dual inhibition profile, actionable protocol guidance, and the latest biomarker insights for ALS.

• HyperScript™ Reverse Transcriptase: Optimizing cDNA Synthesi

  2026-05-22

  HyperScript™ Reverse Transcriptase empowers precise cDNA synthesis from challenging RNA templates, enabling ultra-sensitive qPCR and transcriptomics workflows. Its thermal stability and high affinity deliver robust performance where traditional M-MLV reverse transcriptases struggle.

• LY364947: TGF-β Type I Receptor Kinase Inhibitor for EMT Res

  2026-05-22

  LY364947 enables precise modulation of the TGF-β pathway, offering unmatched reliability for epithelial-mesenchymal transition (EMT) and retinal degeneration studies. Streamlined protocols, robust inhibition of Smad2 phosphorylation, and practical troubleshooting tips make it the preferred choice for researchers seeking reproducibility and mechanistic clarity.

• Viral Induction of RIPK3 Degradation Modulates Necroptosis a

  2026-05-21

  Liu et al. reveal a viral strategy for suppressing necroptosis by targeting the necroptosis adaptor RIPK3 for ubiquitin-proteasome-mediated degradation. This work uncovers a key host-pathogen interaction that shapes viral replication and immune response, with broad implications for studies on protein degradation and innate immunity.

• Cy3-UTP in LNP Tracking: Illuminating RNA Delivery Pathways

  2026-05-21

  Explore how Cy3-UTP, a Cy3-modified uridine triphosphate, revolutionizes RNA tracking within lipid nanoparticles (LNPs). This in-depth analysis connects fluorescence RNA labeling with advanced intracellular delivery research, providing practical assay guidance and new insights for RNA-protein interaction studies.

• CK2 and ERK8 Inhibitor (SKU B7464): Reliable Kinase Modulati

  2026-05-20

  This article provides scenario-driven guidance for using the CK2 and ERK8 inhibitor (SKU B7464), a high-purity, DMSO-soluble small molecule reagent. By addressing real-world pain points in cell viability and signaling research, it demonstrates how SKU B7464 ensures reproducibility and robust data, supporting biomedical researchers seeking reliable kinase inhibition.

• Novobiocin Sodium in Advanced DNA and Antiparasitic Research

  2026-05-20

  Novobiocin Sodium, a powerful aminocoumarin antibiotic from APExBIO, is redefining DNA damage and antiparasitic workflows with high selectivity and low host toxicity. Its versatility in metabolic enzyme research and apoptosis signaling enables streamlined, reproducible protocols for complex cellular studies.

• (S)-(+)-Dimethindene maleate: Technical Guidance for M2 Anta

  2026-05-19

  (S)-(+)-Dimethindene maleate addresses the need for a selective M2 muscarinic receptor antagonist with additional H1 receptor blockade, facilitating precise dissection of autonomic, cardiovascular, and respiratory pathways in preclinical research. It is not suitable for diagnostic or therapeutic use and should not be applied in protocols requiring long-term solution stability.

• Crizotinib Hydrochloride in Tumor Microenvironment Modeling

  2026-05-19

  Explore how Crizotinib hydrochloride, a leading ALK kinase inhibitor, empowers cutting-edge research on tumor microenvironments and drug resistance. This article reveals practical insights for cancer biology research and advanced assembloid models.

• Pharmacokinetics of Vernakalant Hydrochloride and CYP2D6 Imp

  2026-05-18

  This article examines the pharmacokinetic profile of Vernakalant Hydrochloride (RSD1235) as detailed by Mao et al., focusing on the influence of CYP2D6 genotype and related factors in atrial fibrillation patients. The study's findings clarify dosing implications and the negligible role of CYP2D6 status in acute intravenous use, providing a robust foundation for translational and clinical research.

• SB743921: Precision KSP Inhibition for Translational Oncolog

  2026-05-18

  Explore how SB743921, a leading kinesin spindle protein inhibitor, enables next-generation cancer research through mechanistic clarity, robust in vitro modeling, and actionable guidance for translational teams. This article bridges emerging evidence with strategic recommendations—framing SB743921 as an indispensable tool for dissecting mitotic arrest and anti-proliferative responses in preclinical oncology.

• Y-27632 Dihydrochloride: Applied ROCK Inhibition Workflows

  2026-05-17

  Y-27632 dihydrochloride is a benchmark ROCK inhibitor empowering researchers to enhance stem cell viability and suppress tumor invasion through precise cytoskeletal modulation. This article delivers actionable protocols, troubleshooting, and advanced use-case insights—bridging seminal pluripotency research with optimized experimental design.

• Quinolone–Coumarin Hybrids and Novobiocin Sodium Target T. g

  2026-05-16

  This study presents quinolone–coumarin hybrids, synthesized from fluoroquinolones and Novobiocin, as promising anti-parasitic agents against Toxoplasma gondii. The hybrids and Novobiocin displayed high selectivity and efficacy in vitro, suggesting potential for safer antiparasitic drug development.

• RG7388 MDM2 Antagonist: Applied Workflows & Troubleshooting

  2026-05-15

  RG7388, a highly potent and selective MDM2 antagonist, empowers researchers to achieve precision p53 pathway activation and robust cancer cell apoptosis induction in wild-type p53 models. This guide details stepwise experimental workflows, advanced synergy strategies, and actionable troubleshooting, leveraging RG7388's unique advantages for translational oncology research.

• Bufalin: Mechanistic Insights and Strategic Leverage in TNBC

  2026-05-15

  Explore how Bufalin, a cardiotonic steroid, redefines translational cancer research. This in-depth article unpacks mechanistic evidence, strategic protocol guidance, and competitive positioning, focusing on Bufalin’s role as an apoptosis inducer and molecular glue degrader targeting STK33 in triple-negative breast cancer. Designed for translational scientists, this thought-leadership piece delivers actionable intelligence and distinguishes itself from generic product write-ups by offering advanced, evidence-labeled recommendations.

7968 records 12/532 page Previous Next First page 上5页 1112131415 下5页 Last page